Introduction Macular telangiectasia (MacTel) is an insidious neurodegenerative disorder with a characteristic angiographic pattern and localized manifestations. It belongs to a heterogeneous group of rare disorders that characteristically involve the perifoveal microvasculature, collectively referred to as idiopathic macular telangiectasia. This heterogeneity is reflected in the variable nomenclature introduced over the years, after the first cases were reported by Dr. Reese in 1956. Dr. Gass and colleagues were the first to recognize three main disease types 1, 2, and 3, each with subcategories based on demographic, clinical, angiographic, and prognostic criteria. With the addition of optical coherence tomography (OCT) features, a revised classification system was proposed with two disease phenotypes: macular aneurysmal telangiectasia (type 1) and macular perifoveal telangiectasia (type 2), while omitting the rarest “occlusive” (type 3) variant.
Currently, the acronym MacTel is typically encountered in the context of the most common among those disease types, the perifoveal or type 2. Since 2005, this particular entity is being robustly investigated via a worldwide scientific initiative, led by the MacTel Research Group and sponsored by the Lowy Medical Research Institute. In 2022, Dr. Chew and colleagues from this group introduced a novel classification system to stratify MacTel severity. This system was based on an algorithm correlating findings from multimodal retinal imaging studies, including stereoscopic color fundus and red-free photographs, fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral-domain (SD)-OCT, with prospectively-recorded changes in best-corrected visual acuity (VA). It comprises a 7-grade severity scale, where the individual steps are defined by the presence of ellipsoid zone (EZ) disruptions, pigmentary changes, and OCT hyperreflectivities, along with the anatomic involvement of the foveal center around a 0.5 mm radius. Recently, this system’s diagnostic accuracy was tested alongside a deep-learning model, which generated a continuous MacTel severity scale and grading.
Classification of Macular Telangiectasia Type 2 (MacTel)
MacTel Classification Criteria
Grade
Description
0
No EZ Break / No Pigmentation / No OCT HR
1
Noncentral EZ Break / No pigment / No OCT HR
2
Central EZ break / No pigment / No OCT HR
3
Noncentral pigment / No, non-central, or central EZ / No OCT HR
4
OCT HR / EZ break (either central or noncentral) / No pigment
5
Central pigment / no exudative neovascularization / EZ present or not gradable
6
Neovascularization (exudative) ± central pigment
✓Noncentral: Central subfield of International Classification grid unaffected.
EZ = Ellipsoid Zone | HR = Hyper-reflectivity
The reported prevalence of MacTel varies, ranging from 0.004 to 0.1% in geographically distinct populations. Higher rates have been recorded via examination of mydriatic versus non-dilated fundus photographs. Patients are typically diagnosed between the fifth and sixth decades of life, with a predilection for females.
Comorbidities & Risk Factors
Associations with age-related comorbidities and vascular risk factors have been reported:
✓Hypertension (HTN) — Reported as the strongest association.
✓Diabetes Mellitus (DM)
✓Obesity
✓Smoking
Vascular management is a critical component of the systemic clinical profile for these patients.
Clinically, the temporal perifovea appears to be preferentially affected, especially in the early stages; though ultimately, the disease can expand circumferentially to involve the entire fovea including the foveola. MacTel is typically bilateral, although some degree of asymmetry is observed in terms of lesion size and associated symptomatology. There is also strong evidence indicating that microperimetry defects precede the VA decline attributed to MacTel.
Early Diagnostic Indicators
Evidence highlights two critical findings that often precede visible changes on biomicroscopy:
✓Microperimetry Defects: Frequently precede the visual acuity (VA) decline.
✓Early-Phase FA: Shows telangiectasia specifically in the temporal perifovea.
FA findings are often detectable before signs appear on clinical biomicroscopy.
Clinical & Structural Findings
Biomicroscopy
✓Loss of retinal transparency & Crystalline deposits
✓Right-angled venules (Temporal predilection)
✓Pigment proliferations
Multimodal Imaging
✓OCT: Inner retinal clefts under an “ILM drape”
✓Confocal Blue Reflectance: Pathognomonic increased reflectivity
✓FAF: Loss of normal FAF attenuation
Terminology: MP = Macular Pigment; ILM = Internal Limiting Membrane; FAF = Fundus Autofluorescence; EZ = Ellipsoid Zone.
Studies using OCT angiography (OCT-A) have reported vascular abnormalities in both the retinal and the choroidal circulations supplying the foveal region in MacTel patients. Specifically, retinal capillary disruptions in the middle layers corresponding to the deep capillary plexus (DCP) have been consistently detected, and likely associated with early MacTel; meanwhile, as the disease progresses, capillary changes have been found to extend towards the superficial plexus, accompanied by capillary thinning and obliteration, along with outer retina neovascularization (NV), decreased choriocapillaris perfusion, chorioretinal anastomoses, and retinal-choroidal anastomoses without evidence of choroidal NV.
Diagnostic confirmation requires FA, which remains the gold standard and should be strongly considered in patients raising clinical suspicion for MacTel. Currently, no definitive treatment is available. Intravitreal anti-vascular endothelial growth factor (VEGF) is used in cases with associated NV.
Therapeutic Breakthroughs
FDA Approved
March 7, 2025
The U.S. FDA has approved a novel surgical management for MacTel based on Phase 3 clinical trial success:
✓Therapy: Gradual release of recombinant CNTF (Ciliary Neurotrophic Factor).
✓Mechanism: Sustained neuroprotection to decelerate photoreceptor cell death.
Provides a sustained supply of CNTF to preserve retinal structure.
Of note, retina specialists currently view MacTel as a primarily neurodegenerative process, rather than a vascular abnormality. However, the scarcity in treatment and prevention strategies reflects the lack of thorough understanding of MacTel pathophysiology.
Histopathology:
Timeline: MacTel Human Histopathology
1980 – 2004: Vascular & Membrane Focus
✓1980: First report; identified capillary basement membrane (BM) thickening and inner retinal edema.
✓1999: Reported telangiectatic capillaries and RPE hyperplasia.
✓Pathognomonic Halo: Hypo-chromatic perifoveal halo seen on macrophotography and FAF.
✓Blue Reflectance: Hyper-reflectivity often precedes visible vascular lesions.
✓Specific Localization: Unlike Sjogren-Larsson Syndrome, MacTel loss is typically perifoveal.
The Müller Cell Connection
Evidence suggests MP depletion is a secondary effect of primary cellular failure:
✓Primary Insult: Loss of Müller cells (which house MP) leads to pigment displacement.
✓Ineffective Supplementation: Oral lutein fails to restore levels because “storage cells” are missing.
✓Vulnerability: Loss of MP leaves photoreceptors unprotected against oxidative stress.
Clinical Insight: The slow decline in visual acuity in MacTel may be explained by this progressive loss of neuroprotection rather than acute vascular failure.
Müller Cell & Serine Metabolism
The L-Serine Biosynthetic Pathway
Müller cells are the primary producers of L-serine in the retina, a molecule vital for photoreceptor survival:
✓Genetic Risk: Variants in PHGDH (rate-limiting enzyme) predispose patients to serine deficiency.
✓Neurotoxicity: Low serine levels lead to toxic deoxysphingolipids production.
This model explains why MacTel presents in adulthood despite having a genetic component.
Models of Neurotoxicity: HSAN1 & DPN
Shared Pathological Features
MacTel shares biochemical hallmarks with HSAN1 and Diabetic Peripheral Neuropathy (DPN):
✓Substrate Shift: SPT mutations or low serine levels favor L-alanine.
✓DSL Accumulation: Production of atypical, neurotoxic deoxysphingolipids.
✓Multifactorial Nature: Toxicity requires at least “two hits.”
Therapeutic Observations
Condition
Oral L-Serine Result
HSAN1
Reduced circulating DSLs; no functional improvement.
DPN (Rat)
Improved mechanical sensitivity; not yet clinical.
The “Two-Factor” Requirement: Local tissue factors and concurrent metabolic stressors (like aging or ischemia) are likely decisive in triggering neurotoxicity.
The Temporal Perifovea: Why There?
1. The Retinal “Watershed” Zone
✓Developmental Weakness: Temporal capillaries form via complex anastomoses, making them prone to anomalies.
✓Horizontal Raphe: This area is a physiological “watershed” (end-of-the-line for blood flow).
✓Lack of Backup: Unlike the nasal retina, the temporal side lacks the radial peripapillary plexus.
✓Highest Oxygen Demand: Perifoveal photoreceptors consume more oxygen than foveal cones.
✓Müller Cell Stress: Macular Müller cells have lower antioxidant defenses than those in the periphery.
The Theoretical Model: When systemic stressors (Hypertension, Diabetes) hit the Temporal Perifovea, its fragile vascular “end-zone” fails. This unmasks genetic serine defects, forcing Müller cells to choose between their own survival and sustaining the photoreceptors.
Clinicopathologic Comparisons
Retinal Watershed Disorders
The temporal perifoveal predilection in MacTel is reinforced by other conditions that target high-resistance zones:
✓Sickle Cell Retinopathy: Temporal abnormalities due to high vascular resistance.
Key Distinction: While both diseases involve Müller cell failure, TR is a toxic insult that can stabilize. MacTel is a metabolic collapse that worsens over time.
The “Second Hit” & Pathogenesis
The Diagnostic Window (Ages 50–60)
MacTel emerges when systemic comorbidities overlap with localized anatomical vulnerabilities:
Hypertension
Diabetes
Smoking
Obesity
The Dual-Factor Hypothesis
✓Factor 1: Genetic Predisposition — Impaired de novo serine synthesis (PHGDH defects) remains clinically silent for decades.
✓Factor 2: Acquired Ischemia — Systemic vascular stressors compromise nutrient delivery in the temporal watershed zone.
Metabolic Collapse: Under ischemic stress, Müller cells exhaust their own glycogen and serine to sustain photoreceptors. This leads to Müller cell death (cavitations), followed by progressive vision loss.
Vascular & Neovascular Paradoxes
The “Dry” Leakage Mystery
Unlike Diabetes, MacTel shows leakage on FA but no significant Macular Edema (ME) on OCT.
✓Size-Selective Permeability: Leaks allow small Fluorescein molecules to pass, but hold back large Albumin proteins.
✓Minimal VEGF Signal: The slow “starvation” of cells doesn’t trigger the massive VEGF spike seen in acute cases.
The Anti-VEGF Dilemma
⚠️ Clinical Warning: In non-proliferative stages, VEGF acts as a survival factor. Blocking it may accelerate atrophy.
Proliferative Phenotypes
Feature
MacTel (Late)
Type 3 MNV
Initial Sign
EZ/Photoreceptor loss
Edema & Exudation
Ischemia
Mild / Chronic
Severe / Acute
Key Conclusion: Telangiectasia is a symptom of the dying retina, not the primary cause of the disease.
Future Research Directions
1. Clinical-Histologic Correlation
Adopt the high-resolution “mapping” approach used in AMD research:
✓Lifelong Imaging: Correlate serial SD-OCT/OCT-A scans with postmortem tissue findings.
✓Biomarker Discovery: Identify imaging markers that predict future atrophy or MNV.
2. Precision Methodology
Focus Area
Recommendation
Tissue Fixation
Fixation within 6h postmortem to preserve capillaries.
Vascular Mapping
Cannulation for 3D confocal imaging of vessels.
Analysis
Automated Müller cell quantification via AI/ImageJ.
Collaborative Goal: Bridge specialized retinal centers and eye banks to create a “Natural History Registry” matching genetic data with standardized multimodal imaging.
Moving from descriptive to quantitative histopathology is the key to solving the MacTel puzzle.
Treatment Frontiers: Neuroprotection
Current Therapeutic Landscape
CNTF Implant (Encelto):
FDA-approved. Shows significant Ellipsoid Zone (EZ) preservation. It aims to “rescue” stressed photoreceptors.
Oral Serine & Fenofibrate:
Ongoing Phase 2 trials. Designed to reduce toxic deoxysphingolipids by normalizing the metabolic substrate.
The “Empty House” Problem
Supplementation may fail if the host cells (Müller cells) are already lost:
•Homeostasis First: Focus must be on keeping Müller cells alive before they degenerate.
•Metabolic Signaling: Serine acts through complex pathways, not just simple volume replacement.
Cross-Disorder Insights
The ATM Connection: Variants in the ATM gene increase MacTel risk, suggesting that ferroptosis inhibitors or DNA-repair antioxidants could be the next frontier in treatment.
The future of MacTel therapy lies in early upstream intervention to stabilize the “metabolic engine” of the macula.
The Integrated Model of MacTel
From Histopathology to Personalized Neuroprotection
Pathogenic Foundations
1. The Genetic “Seed”
Subclinical defects in PHGDH impair the Serine pathway in Müller cells. This remains silent for decades.
2. The Ischemic “Hit”
Age-related vascular stressors cause chronic hypoperfusion in the temporal watershed zone.
The Diagnostic Triad
1Macular Pigment Depletion: A clinical marker of Müller cell failure.
2Müller Cell Atrophy: The primary lesion causing “cavitations” on OCT.
3Temporal Predilection: Due to unique watershed anatomy.
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
Connect with
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
very interesting and comprehensive information!
image: a patient with MacTel type 2 and crystalline abnormalities. The hyperreflective crystals on SD_OCT are at the level of the ILM.
very interesting and comprehensive information!
image: a patient with MacTel type 2 and crystalline abnormalities. The hyperreflective crystals on SD_OCT are at the level of the ILM..
very interesting and comprehensive information!
image: a patient with MacTel type 2 and crystalline abnormalities. The hyperreflective crystals on SD_OCT are at the level of the ILM.
very interesting and comprehensive information!
image: a patient with MacTel type 2 and crystalline abnormalities. The hyperreflective crystals on SD_OCT are at the level of the ILM..